HOLLISTON, Mass., Feb. 23, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2016 after market trading hours on Thursday, March 9, 2017. A conference call to discuss the company's fourth quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 44422279.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 16, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
Want to cut your energy bills? Here’s how five experts are doing it
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 



